Article thumbnail

Comprehensive cardiovascular risk management – what does it mean in practice?

By Leif Erhardt, Robert Moller and Juan García Puig

Abstract

The continued movement away from the treatment of individual cardiovascular (CV) risk factors to managing overall and lifetime CV risk is likely to have a significant impact on slowing the rate of increase in cardiovascular disease (CVD). However, the management of CVD is currently far from optimal even in parts of the world with well-developed and well-funded healthcare systems. Effective implementation of the knowledge, treatment guidelines, diagnostic tools, therapeutic interventions, and management programs that exist for CVD continues to evade us. A thorough understanding of the multifactorial nature of CVD is essential to its effective management. Improvements continue to be made to management guidelines, risk assessment tools, treatments, and care programs pertaining to CVD. Ultimately, however, preventing the epidemic of CVD will require a combination of both medical and public health approaches. In addition to improvements in the “high-risk” strategy, management, an increase in the utilization of population-based management strategies needs to be made to attempt to reduce the number of patients falling within the “at-risk” stratum for CVD. This review outlines how a comprehensive approach to CVD management might be achieved

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2291303
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A multidimensional integrative medicine intervention to improve cardiovascular risk.
  2. (2001). A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials; PRECARD and the Copenhagen Risk Score.
  3. (2003). A strategy to reduce cardiovascular disease by more than 80%.
  4. (2002). Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in fi ve European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract,
  5. (2002). Adherence to statin treatment and readmission of patients after myocardial infarction:a six year follow up study.
  6. (1997). Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study.
  7. (2006). Behavior-change action plans in primary care: a feasibility study of clinicians.
  8. (1994). Blood pressure, antihypertensive treatment and stroke risk. J Hypertens Suppl,
  9. (1994). By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease.
  10. (2006). Canadian hypertension education program recommendations for the management of hypertension: Part II – Therapy.
  11. (1987). Cardiovascular morbidity in relation to change in blood pressure and serum cholesterol levels in treated hypertension. Results from the primary prevention trial in Goteborg,
  12. (2006). Cardiovascular risk meter: A device for rapid estimation of cardiovascular disease mortality in clinical settings.
  13. (1999). Challenges to best practice: Why are guidelines not implemented.
  14. (1998). Changes in premature deaths in Finland:successful long-term prevention of cardiovascular diseases.
  15. (1994). Changes in risk factor explain changes in mortality from ischaemic heart disease in Finland.
  16. (2001). Clinical reality of coronary prevention guidelines:a comparison of EUROASPIRE I and II in nine countries.
  17. (2002). Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55 years) men and women.
  18. (2004). Comparison of two methods of presenting risk information to patients about the side effects of medicines. Qual Saf Health Care,
  19. (1988). Comprehensive cardiovascular community control programmes
  20. (2005). Cost-effectiveness of lipid-lowering treatment according to lipid level.
  21. (2006). Cost-related medication nonadherence among elderly and disabled Medicare benefi ciaries: a national survey 1 year before the medicare drug benefi t.
  22. (1996). Detection and prevention of cardiac risk factors:health risk assessment and targeted follow-up in a managed care population. J Cardiovasc Nurs,
  23. (1993). Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care,
  24. (2003). Drug prescriptions after acute myocardial infarction:dosage, compliance, and persistence.
  25. (2004). Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial.
  26. (2006). Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.
  27. (2004). Effect of potentially modifi able risk factors associated with myocardial infarction in 52 countries (the INTERHEART study):case-control study.
  28. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events:results of prospectively-designed overviews of randomised trials.
  29. (1996). Effects of pressure-induced stretch and convection on low-density lipoprotein and albumin uptake in the rabbit aortic wall. Circ Res,
  30. (2005). Effi cacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
  31. (2006). Effi cacy of psychosocial interventions for smoking cessation in patients with coronary heart disease:a systematic review and meta-analysis. Ann Behav Med,
  32. (2003). Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol,
  33. (2003). Estimation of ten-year risk of fatal cardiovascular disease
  34. (2004). Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study.
  35. European Action on Secondary Prevention by Intervention to Reduce Events.
  36. (2000). European Cardiovascular Disease Statistics.
  37. (2003). European guidelines on cardiovascular disease prevention in clinical practice.
  38. (2004). Evaluating the impact of population and high-risk strategies for The primary prevention of cardiovascular disease.
  39. (2005). Evidence for a combined approach to the management of hypertension and dyslipidemia.
  40. (2006). Excess of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.
  41. (2001). Executive Summary of The Third Report
  42. (2005). Expanding the defi nition and classifi cation of hypertension. J Clin Hypertens,
  43. (2000). Fifty years of Framingham Study contributions to understanding hypertension.
  44. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care,
  45. (2004). Guidelines and their implementation: a discussion document focused on the best appraches to drive improvement. Vascular Disease Prevention,
  46. (2007). Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
  47. (2005). Health Organization.
  48. (2006). Healthy lifestyle factors in the primary prevention of coronary heart disease among men.
  49. (2003). Heart Association.
  50. (2007). Heart disease and stroke statistics–2007 update:a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation,
  51. (2001). High blood pressure and associated cardiovascular risk factors in France.
  52. (2004). How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients.
  53. (2003). Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function. Arterioscler Thromb Vasc Biol,
  54. (1996). Hypertension and associated metabolic abnormalities – the role of insulin resistance and the sympathoadrenal system.
  55. (2006). Impact of medication therapy discontinuation on mortality after myocardial infarction.
  56. (2006). Implementation of recommendations on hypertension: the Canadian Hypertension Education Program.
  57. (2003). Implementing behavioral counseling interventions in primary care to modify cardiovascular risk in adults with diabetes. Cardiovasc Rev Rep,
  58. (1997). Improving care with nurse case managers:practical aspects of designing lipid clinics.
  59. (2005). Independent association between infl ammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension.
  60. (2004). Intensive and moderate lipid lowering with statins after acute coronary symptoms.
  61. (2005). INTERHEART: nine factors that could save your life. Healthc Q,
  62. (2006). International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis.
  63. (2006). Knowing your risk factors for coronary heart disease improves adherence to advice on lifestyle changes and medication.
  64. (1996). Links between hypertension and myocardial infarction.
  65. (2000). Lipid concentrations and the use of lipid lowering drugs:evidence from a national cross sectional survey.
  66. (2003). Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment.
  67. (2003). Major risk factors as antecedents of fatal and nonfatal coronary heart disease events.
  68. (2006). Medication costs as a primary cause of nonadherence in the elderly. Consult Pharm,
  69. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.
  70. (2003). Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
  71. (2004). Obstacles to cardiovascular prevention in general practice.
  72. (2002). Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study).
  73. (2004). Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
  74. (1986). Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population.
  75. (1994). Persistence of multiple cardiovascular risk clustering related to syndrome X from childhood to young adulthood. The Bogalusa Heart Study. Arch Intern Med,
  76. (1998). Persistence of use of lipidlowering medications:a cross-national study.
  77. (1998). Prediction of coronary heart disease using risk factor categories.
  78. (2006). Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age.
  79. (2005). Predictors of adherence with antihypertensive and lipid-lowering therapy.
  80. (2004). Presentation of multivariate data for clinical use:The Framingham Study risk score functions. Stat Med,
  81. (2006). Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States.
  82. (2003). Reassessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias.
  83. (2006). Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study.
  84. (2002). Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study.
  85. (2000). Risk stratifi cation in hypertension: new insights from the Framingham Study. Am J Hypertens,
  86. (1998). Secondary prevention clinics for coronary heart disease: randomized trial of effect on health.
  87. (1992). Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall fi ndings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med,
  88. (2003). Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease.
  89. (2005). Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (The Amlodipine/Atorvastatin Gemini Study).
  90. (2005). Societies
  91. Task Force of
  92. (1999). The health economics of the treatment of hyperlipidemia and hypertension.
  93. (2005). The infl ammation: lipoprotein cycle. Atheroscler Suppl,
  94. (2004). The joint effect of hypertension and elevated LDL-cholesterol on CHD is beyond additive. Eur Heart J, 25(abstract suppl):235[abstract #1377].
  95. (2006). The role of global risk assessment in hypertension therapy.
  96. (2003). The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The
  97. (2006). Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care,
  98. (2006). Total cardiovascular risk:a new treatment concept. J Hypertens Suppl,
  99. (2005). Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk.
  100. (2005). Vascular Health and Risk Management 2007:3(5) 602 Erhardt et al
  101. (2005). Vascular Health and Risk Management 2007:3(5) 603 Managing cardiovascular risk in practice
  102. (2006). Why 6g? A summary of the scientifi c evidence for the salt intake target. Cambridge: Medical Research Council.
  103. (1999). Why don’t physicians follow clinical practice guidelines? A framework for improvement.